Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025International Journal of CancerOpen Access

Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients

View Full Paper
Ask AI
Bookmark
Share

Authors

KPKaterina‐Marina PilalaSKStella KoroneouMPM. Papadimitriou

Discussion

Loading...

Member takes

Overview

Analysis reveals loss of METTL3 affects prognosis in bladder cancer patients with NMIBC and MIBC, indicating its clinical significance.

Key Points

  • Loss of METTL3 expression correlates with higher risk of short-term progression in NMIBC and worse survival in MIBC.
  • Reduced METTL3 was linked to muscle-invasive disease and advanced tumor stage, impacting treatment efficacy.
  • Cox regression models incorporating METTL3 improved risk stratification compared to established disease markers.
  • Validation in cohorts confirmed that loss of METTL3 predicts poor treatment outcomes in bladder cancer patients.

Cite This Study

Pilala et al. (2025) studied this question.

synapsesocial.com/papers/68d413f8713b0b5dfea61c42https://doi.org/10.1002/ijc.70147
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unraveling the dual role of METTL3-mediated m <sup>6</sup> A RNA modification in bladder cancer: mechanisms, therapeutic vulnerabilities, and clinical implications2025
  2. 2The methyltransferase METTL3 promotes the progression of breast cancer cells via regulating EGF m6A modification2025
  3. 3METTL3-mediated activation of Sonic Hedgehog signaling promotes breast cancer progression2025
  4. 4A meta analysis of subtype-specific prognostic significance of METTL3 expression in non-small cell lung cancer2025
  5. 5Targeting METTL3 disrupts oncogenic transcriptional programs and activates immune and apoptotic pathways in Acute Myeloid Leukemia2025